PLYMOUTH, Minn., Dec. 8 /PRNewswire-FirstCall/ -- ev3 Inc. (NASDAQ:EVVV), a global endovascular device company, announced today that it expects the previously announced merger of a wholly owned...
ev3 Inc. to Acquire Approximately 29.9% of Shares Not Already Owned PLYMOUTH, Minn., and IRVINE, Calif., Nov. 14 /PRNewswire-FirstCall/ -- ev3 Inc. (NASDAQ:EVVV), a global endovascular device...
- Company Significantly Narrows Net Loss With Growth in Net Sales, Higher Gross Margins and Improved Cost Control - IRVINE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Micro Therapeutics, Inc...
Net Sales Grow by 70% Compared to Year-Ago Period PLYMOUTH, Minn., Oct. 27 /PRNewswire-FirstCall/ -- ev3 Inc. (NASDAQ:EVVV), a global endovascular device company, reported today its financial...
PLYMOUTH, Minn., or IRVINE, Calif., Oct. 21 /PRNewswire-FirstCall/ -- ev3 Inc. (NASDAQ:EVVV) and its majority-owned subsidiary Micro Therapeutics, Inc. (MTI) (NASDAQ:MTIX), will each release its...
Proposes Purchase of Approximately 29.8% of Shares Not Already Owned PLYMOUTH, Minn., Oct. 10 /PRNewswire-FirstCall/ -- ev3 Inc. (NASDAQ:EVVV), a global endovascular device company, announced...
IRVINE, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Micro Therapeutics, Inc. (MTI) (NASDAQ:MTIX), an endovascular medical device company focused on neurovascular disorders of the brain associated...
Net Sales Grow to $14.1 Million, a 72% Increase Compared to Third Quarter 2004 IRVINE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Micro Therapeutics, Inc. (MTI) (NASDAQ:MTIX), an endovascular...
- Joint Conference Call With ev3 Inc. Scheduled for Today at 5:00 p.m. EDT (2:00 p.m. PDT); Simultaneous Webcast at www.1mti.com - IRVINE, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Micro...
Net Sales Grow by 53% Compared to Year-Ago Period PLYMOUTH, Minn., Aug. 2 /PRNewswire-FirstCall/ -- ev3 Inc. (NASDAQ:EVVV), a global endovascular device company, reported today its financial...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales